An Observational Study Evaluating Anti-Idursulfase Serum Antibody Response in Hunter Syndrome Patients

CompletedOBSERVATIONAL
Enrollment

26

Participants

Timeline

Start Date

October 14, 2008

Primary Completion Date

February 8, 2013

Study Completion Date

February 8, 2013

Conditions
Hunter Syndrome
Interventions
BIOLOGICAL

Idursulfase

Patients received idursulfase as prescribed by their physician following locally approved prescribing information. Patients will not be provided idursulfase by Shire Human Genetic Therapies, Inc. or the HOS.

Trial Locations (6)

55404

Children's Hospitals and Clinics of Minnesota, Division of Genetics, Minneapolis

94609

Children's Hospital & Research Center Oakland, Oakland

90035-903

Hospital de Clinicas de Porto Alegre, Servico de Genetica Medica, Porto Alegre

B46NH

Birmingham Children's Hospital, Birmingham

WC1N 3JH

Great Ormond Street Hospital, London

M139WL

Central Manchester University Hospitals, St. Mary's Hospital, Manchester

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Shire

INDUSTRY